Skip to content

Can Advanced-Platelet Rich Fibrin (A-PRF), a patient blood-derived living biomaterial, prevent chronic inflammation after wisdom tooth surgery?

The effect of A-PRF on preventing systemic inflammation: A pilot randomized controlled clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN12738881
Enrollment
20
Registered
2020-12-16
Start date
2020-12-28
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic acute inflammatory response after wisdom tooth removal in otherwise healthy patients Oral Health Systemic Inflammatory Response Syndrome of non-infectious origin without organ failure

Interventions

The test group will undergo third molar removal plus the application of Advanced Platelet-Rich Fibrin (A-PRF) on the alveolar socket. The control group will receive the same procedure

Sponsors

University of Santiago de Compostela
Lead Sponsor
Instituto Superior de Ciências da Saúde Egas Moniz
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Two unilateral fully impacted mandibular third molars which have the same degree of surgical difficulty comparing one side with the other 2. Healthy patients without significant medical diseases or a history of bleeding problems 3. Adequate level of plaque control (plaque index (PI) <15%) 4. Non-smokers patients 5. Able to give written consent

Exclusion criteria

Exclusion criteria: 1. Younger than 18 years old or older than 65 years old 2. Females who were pregnant or lactating 3. Females using contraceptive methods 4. Had any reported systemic illness 5. Had chronic use of any medication within 30 d prior to the study inclusion 6. Affected by periodontitis (Tonetti, Greenwell, & Kornman, 2018) 7. Signs of pericoronitis 8. Removable upper and/or lower partial dentures 9. Had periapical and periradicular radiolucencies that were detected on X-rays

Design outcomes

Primary

MeasureTime frame
Acute inflammatory response measured by hs-C-reactive protein serum levels at 24 h after intervention

Secondary

MeasureTime frame
There are no secondary outcome measures

Countries

Portugal

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026